Sibel KALYONCU, Merve ARSLAN, Dilara KARADAĞ

Protein engineering approaches for antibody fragments: directed evolution and rational design approaches

The number of therapeutic antibodies in preclinical, clinical, or approved phases has been increasing exponentially, mostlydue to their known successes. Development of antibody engineering methods has substantially hastened the development of therapeuticantibodies. A variety of protein engineering techniques can be applied to antibodies to improve their affinity and/or biophysical propertiessuch as solubility and stability. Antibody fragments (where all or some parts of constant regions are eliminated while the essentialantigen binding region is preserved) are more suitable for protein engineering techniques because there are many in vitro screeningtechnologies available for antibody fragments but not full-length antibodies. Improvement of biophysical characteristics is importantin the early development phase because most antibodies fail at the later stage of development and this leads to loss of resources andtime. Here, we review directed evolution and rational design methods to improve antibody properties. Recent developments in rationaldesign approaches and antibody display technologies, and especially phage display, which was recently awarded the 2018 Nobel Prize,are discussed to be used in antibody research and development.

PDF

___

Agrawal NJ, Kumar S, Wang XL, Helk, B, Singh SK, Trout BL (2011). Aggregation in protein-based biotherapeutics: computational studies and tools to identify aggregation-prone Regions. Journal of Pharmaceutical Sciences 100: 5081-5095.
Bain B, Brazil M (2003). Adalimumab. Nature Reviews Drug Discovery 2: 693-694.
Bava KA, Gromiha MM, Uedaira H, Kitajima K, Sarai A (2004). ProTherm, version 4.0: thermodynamic database for proteins and mutants. Nucleic Acids Research 32: D120-D121.
Beerten J, Van Durme J, Gallardo R, Capriotti E, Serpell L, Rousseau F, Schymkowitz J (2015). WALTZ-DB: a benchmark database of amyloidogenic hexapeptides. Bioinformatics 31: 1698-1700.
Bradbury A, Pluckthun A (2015). Standardize antibodies used in research. Nature 518: 27-29.
Brodel AK, Isalan M, Jaramillo A (2018). Engineering of biomolecules by bacteriophage directed evolution. Current Opinion in Biotechnology 51: 32-38.
Capriotti E, Fariselli P, Casadio R (2004). A neural-network-based method for predicting protein stability changes upon single point mutations. Bioinformatics 20: 63-68.
Capriotti E, Fariselli P, Casadio R (2005). I-Mutant2.0: predicting stability changes upon mutation from the protein sequence or structure. Nucleic Acids Research 33: W306-W310.
Chan CE, Lim AP, MacAry PA, Hanson BJ (2014). The role of phage display in therapeutic antibody discovery. International Immunology 26: 649-657.
Chao G, Lau W L, Hackel BJ, Sazinsky SL, Lippow SM, Wittrup KD (2006). Isolating and engineering human antibodies using yeast surface display. Nature Protocols 1: 755-768.
Cheng JL, Randall A, Baldi P (2006). Prediction of protein stability changes for single-site mutations using support vector machines. Proteins-Structure Function and Bioinformatics 62: 1125-1132.
Chiu ML, Gilliland GL (2016). Engineering antibody therapeutics. Current Opinion in Structural Biology 38: 163-173.
Conchillo-Sole O, de Groot NS, Aviles FX, Vendrell J, Daura X, Ventura S (2007). AGGRESCAN: a server for the prediction and evaluation of “hot spots” of aggregation in polypeptides. BMC Bioinformatics 8: 65.
Courtois F, Agrawal NJ, Lauer TM, Trout BL (2016). Rational design of therapeutic mAbs against aggregation through protein engineering and incorporation of glycosylation motifs applied to bevacizumab. MAbs 8: 99-112.
Dubay KF, Pawar AP, Chiti F, Zurdo J, Dobson CM, Vendruscolo M (2004). Prediction of the absolute aggregation rates of amyloidogenic polypeptide chains. Journal of Molecular Biology 341: 1317-1326.
Dudgeon K, Rouet R, Kokmeijer I, Schofield P, Stolp J, Langley D, Stock D, Christ D (2012). General strategy for the generation of human antibody variable domains with increased aggregation resistance. Proceedings of the National Academy of Sciences of the United States of America 109: 10879-10884.
Elgundi Z, Reslan M, Cruz E, Sifniotis V, Kayser V (2017). The stateof-play and future of antibody therapeutics. Advanced Drug Delivery Reviews 122: 2-19.
Enever C, Pupecka-Swider M, Sepp A (2015). Stress selections on domain antibodies: ‘What doesn’t kill you makes you stronger’. Protein Engineering Design & Selection 28: 59-66.
Feldhaus MJ, Siegel RW (2004). Yeast display of antibody fragments: a discovery and characterization platform. Journal of Immunological Methods 290: 69-80.
Fernandez-Escamilla AM, Rousseau F, Schymkowitz J, Serrano L (2004). Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nature Biotechnology 22: 1302-1306.
Fink AL (1998). Protein aggregation: folding aggregates, inclusion bodies and amyloid. Folding & Design 3: R9-R23.
Frenzel A, Kugler J, Helmsing S, Meier D, Schirrmann T, Hust M, Dubel S (2017). Designing human antibodies by phage display. Transfusion Medicine and Hemotherapy 44: 312-318.
García Merino A (2011). Monoclonal antibodies. Basic features. Neurología (English Edition) 26: 301-306.
Gasior P, Kotulska M (2014). FISH Amyloid - a new method for finding amyloidogenic segments in proteins based on site specific cooccurrence of aminoacids. BMC Bioinformatics 15: 54.
Georgiou G, Poetschke HL, Stathopoulos C, Francisco JA (1993). Practical applications of engineering gram-negative bacterialcell surfaces. Trends in Biotechnology 11: 6-10.
Groves MAT, Amanuel L, Campbell JI, Rees DG, Sridharan S, Finch DK, Lowe DC, Vaughan TJ (2014). Antibody VH and VL recombination using phage and ribosome display technologies reveals distinct structural routes to affinity improvements with VH-VL interface residues providing important structural diversity. MAbs 6: 236-245.
Gustafson HH, Olshefsky A, Sylvestre M, Sellers DL, Pun SH (2018). Current state of in vivo panning technologies: Designing specificity and affinity into the future of drug targeting. Advanced Drug Delivery Reviews 130: 39-49.
Hairul Bahara NH, Tye GJ, Choong YS, Ong EB, Ismail A, Lim TS (2013). Phage display antibodies for diagnostic applications. Biologicals 41: 209-216.
Hanes J, Pluckthun A (1997). In vitro selection and evolution of functional proteins by using ribosome display. Proceedings of the National Academy of Sciences of the United States of America 94: 4937-4942.
Harel Inbar N, Benhar I (2012). Selection of antibodies from synthetic antibody libraries. Archives of Biochemistry and Biophysics 526: 87-98.
Hebditch M, Carballo-Amador MA, Charonis S, Curtis R, Warwicker J (2017). Protein-Sol: a web tool for predicting protein solubility from sequence. Bioinformatics 33: 3098-3100.
Ho M, Nagata S, Pastan I (2006). Isolation of anti-CD22 Fv with high affinity by Fv display on human cells. Proceedings of the National Academy of Sciences of the United States of America 103: 9637- 9642.
Ho M, Pastan I (2009). Mammalian cell display for antibody engineering. Methods in Molecular Biology 525: 337-352.
Jeong KJ, Seo MJ, Iverson BL, Georgiou G (2007). APEx 2-hybrid, a quantitative protein-protein interaction assay for antibody discovery and engineering. Proceedings of the National Academy of Sciences of the United States of America 104: 8247-8252.
Jijakli K, Khraiwesh B, Fu W, Luo L, Alzahmi A, Koussa J, Chaiboonchoe A, Kirmizialtin S, Yen L, Salehi-Ashtiani K (2016). The in vitro selection world. Methods 106: 3-13.
Kamtekar S, Schiffer JM, Xiong HY, Babik JM, Hecht MH (1993). Protein design by binary patterning of polar and nonpolar amino-acids. Science 262: 1680-1685.
Kaplon H, Reichert JM (2018). Antibodies to watch in 2018. MAbs 10: 183-203.
Karimi M, Mirshekari H, Moosavi Basri SM, Bahrami S, Moghoofei M, Hamblin MR (2016). Bacteriophages and phage-inspired nanocarriers for targeted delivery of therapeutic cargos. Advanced Drug Delivery Reviews 106: 45-62.
Kiguchi Y, Oyama H, Morita I, Katayama E, Fujita M, Narasaki M, Yokoyama A, Kobayashi N (2018). Antibodies and engineered antibody fragments against M13 filamentous phage to facilitate phage-display-based molecular breeding. Biological & Pharmaceutical Bulletin 41: 1062-1070.
Ledsgaard L, Kilstrup M, Karatt-Vellatt A, McCafferty J, Laustsen AH (2018). Basics of antibody phage display technology. Toxins (Basel) 10: E236.
Li W, Caberoy NB (2010). New perspective for phage display as an efficient and versatile technology of functional proteomics. Applied Microbiology and Biotechnology 85: 909-919. Liu R, Li X, Xiao W, Lam KS (2017). Tumor-targeting peptides from combinatorial libraries. Advanced Drug Delivery Reviews 110- 111: 13-37.
Loset GA, Sandlie I (2012). Next generation phage display by use of pVII and pIX as display scaffolds. Methods 58: 40-46.
Mei M, Zhou Y, Peng W, Yu C, Ma L, Zhang G, Yi L (2017). Application of modified yeast surface display technologies for non-Antibody protein engineering. Microbiological Research 196: 118-128.
Nagumo Y, Fujiwara K, Horisawa K, Yanagawa H, Doi N (2016). PURE mRNA display for in vitro selection of single-chain antibodies. Journal of Biochemistry 159: 519-526.
Nelson AL (2010). Antibody fragments: hope and hype. MAbs 2: 77- 83. Nixon AE, Sexton DJ, Ladner RC (2014). Drugs derived from phage display: from candidate identification to clinical practice. MAbs 6: 73-85.
Paladin L, Piovesan D, Tosatto SCE (2017). SODA: prediction of protein solubility from disorder and aggregation propensity. Nucleic Acids Research 45: W236-W240.
Pandurangan AP, Ochoa-Montano B, Ascher DB, Blundell TL (2017). SDM: a server for predicting effects of mutations on protein stability. Nucleic Acids Research 45: W229-W235.
Parthiban V, Gromiha MM, Schomburg D (2006). CUPSAT: prediction of protein stability upon point mutations. Nucleic Acids Research 34: W239-W242.
Pawar AP, DuBay KF, Zurdo J, Chiti F, Vendruscolo M, Dobson CM (2005). Prediction of “aggregation-prone” and “aggregation-susceptible” regions in proteins associated with neurodegenerative diseases. Journal of Molecular Biology 350: 379-392.
Pires DEV, Ascher DB (2016). mCSM-AB: a web server for predicting antibody-antigen affinity changes upon mutation with graphbased signatures. Nucleic Acids Research 44: W469-W473.
Qin CF, Li GC (2014). Mammalian cell display technology coupling with AID induced SHM in vitro: an ideal approach to the production of therapeutic antibodies. International Immunopharmacology 23: 380-386.
Sergeeva A, Kolonin MG, Molldrem JJ, Pasqualini R, Arap W (2006). Display technologies: application for the discovery of drug and gene delivery agents. Advanced Drug Delivery Reviews 58: 1622- 1654.
Smith GP (1985). Filamentous fusion phage - novel expression vectors that display cloned antigens on the virion surface. Science 228: 1315-1317.
Sormanni P, Amery L, Ekizoglou S, Vendruscolo M, Popovic B (2017). Rapid and accurate in silico solubility screening of a monoclonal antibody library. Scientific Reports 7: 8200.
Sormanni P, Aprile FA, Vendruscolo M (2015). The CamSol method of rational design of protein mutants with enhanced solubility. Journal of Molecular Biology 427: 478-490.
Stohl W, Hilbert DM (2012). The discovery and development of belimumab: the anti-BLyS-lupus connection. Nature Biotechnology 30: 69-77.
Swindells MB, Porter CT, Couch M, Hurst J, Abhinandan KR, Nielsen JH, Macindoe G, Hetherington J, Martin ACR (2017). abYsis: Integrated antibody sequence and structure-management, analysis, and prediction. Journal of Molecular Biology 429: 356- 364.
Tartaglia GG, Vendruscolo M (2008). The Zyggregator method for predicting protein aggregation propensities. Chemical Society Reviews 37: 1395-1401.
Teixeira D, Gonzalez-Pajuelo, M (2018). Phage display technology for selection of antibody fragments. In: Sarmento B, Das Neves J (editors). Biomedical Applications of Functionalized Nanomaterials. Amsterdam, the Netherlands: Elsevier, pp. 67-88.
Thiltgen G, Goldstein RA (2012). Assessing predictors of changes in protein stability upon mutation using self-consistency. PLoS One 7: e46084.
van der Kant R, van der Kant R, Karow-Zwick AR, Durme JV, Blech M, Gallardo R, Seeliger D, Aßfalg K, Baatsen P, Compernolle G et al. (2017). Prediction and reduction of the aggregation of monoclonal antibodies. Journal of Molecular Biology 429: 1244- 1261.
Wainreb G, Wolf L, Ashkenazy H, Dehouck Y, Ben-Tal N (2011). Protein stability: a single recorded mutation aids in predicting the effects of other mutations in the same amino acid site. Bioinformatics 27: 3286-3292.
Walsh I, Seno F, Tosatto SCE, Trovato A (2014). PASTA 2.0: an improved server for protein aggregation prediction. Nucleic Acids Research 42: W301-W307.
Wang XL, Singh SK, Kumar S (2010). Potential aggregation-prone regions in complementarity-determining regions of antibodies and their contribution towards antigen recognition: a computational analysis. Pharmaceutical Research 27: 1512-1529.
West MW, Wang WX, Patterson J, Mancias J D, Beasley JR, Hecht MH (1999). De novo amyloid proteins from designed combinatorial libraries. Proceedings of the National Academy of Sciences of the United States of America 96: 11211-11216.
Worn A, Pluckthun A (1999). Different equilibrium stability behavior of ScFv fragments: identification, classification, and improvement by protein engineering. Biochemistry 38: 8739- 8750.
Worn A, Pluckthun A (2001). Stability engineering of antibody single-chain Fv fragments. Journal of Molecular Biology 305: 989-1010.
Xiao XD, Chen Y, Mugabe S, Gao C, Tkaczyk C, Mazor Y, Pavlik P, Wu H, Dall’Acqua W, Chowdhury PS (2017). A highthroughput platform for population reformatting and mammalian expression of phage display libraries to enable functional screening as full-length IgG. MAbs 9: 996-1006.
Yageta S, Lauer TM, Trout BL, Honda S (2015). Conformational and colloidal stabilities of isolated constant domains of human immunoglobulin G and their impact on antibody aggregation under acidic conditions. Molecular Pharmaceutics 12: 1443- 1455.
Yang Y, Niroula A, Shen BR, Vihinen M (2016). PON-Sol: prediction of effects of amino acid substitutions on protein solubility. Bioinformatics 32: 2032-2034.
Zambrano R, Jamroz M, Szczasiuk A, Pujols J, Kmiecik S, Ventura S (2015). AGGRESCAN3D (A3D): server for prediction of aggregation properties of protein structures. Nucleic Acids Research 43: W306-W313.